Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cardium Therapeutics has signed an investment agreement with SourceOne Global Partners, a provider of science-based ingredients, to develop and commercialize nutritional supplements, pharmaceuticals and medical foods based on SourceOne's branded ingredients.
Subscribe to our email newsletter
The ingredients by SourceOne comprise specialized formulations of EPA/DHA Omega-3 oils, Citrus Polymethoxylated Flavonoids, TocoSource Palm Tocotrienols, and VESIsorb (which is designed to enhance bioavailability of a variety of nutraceutical ingredients and dietary supplements).
Cardium chairman and CEO Christopher Reinhard said the collaboration would help expand their MedPodium healthy lifestyle brand platform, and develop nutritional supplements, as well as pharmaceuticals and medical foods through appropriate commercialization pathways.
As per the agreement, Cardium has made a $0.75 million equity investment in the form of unregistered, restricted Cardium shares to acquire rights to a 15% ownership interest in SourceOne Global Partners.